SVFC News Friday, May 30, 2014 8:45:58 PM

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
SVFC News Friday, May 30, 2014 8:45:58 PM $SVFC

IntelliCell BioSciences announces That Merril Hoge has joined Its Board of Advisors
PR Newswire - Tue May 13, 10:45AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that Merril Hoge, former star NFL player and an on-air analyst for ESPN, has joined its Board of Advisors.

IntelliCell BioSciences Announces Positive Final Ruling Against Ironridge Global IV, LTD., and TCA Global Credit Master Fund, LP
PR Newswire - Wed May 07, 8:45AM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has received a final positive ruling in its case against Ironridge Global IV, LTD. ("Ironridge" , and TCA Global Credit Master Fund, LP ("TCA" .

IntelliCell BioSciences' Stromal Vascular Cell Technology Used For Restorative Cardiac Function With Dr. Zain Khalpey
PR Newswire - Tue Apr 29, 12:32PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous Stromal Vascular Cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it supplied its Stromal Vascular Fraction Cells, manufactured using its patented ultrasonic technology, for the restoration of cardiac function at the University of Arizona College of Medicine, Tucson in collaboration with Dr. Zain Khalpey, Division of Cardiothoracic Surgery. The autologous cells were gathered on site with Institutional Review Board approval in accordance with all applicable regulatory requirements. The case was reported in Clinical Communication to the Editor in The American Journal of Medicine Vol.127, No 5, May 2014.

inVentiv Health Clinical Engaged by IntelliCell Biosciences, a Regenerative Medicine Company, as Clinical Research Organization for Osteoarthritis IND
PR Newswire - Tue Apr 15, 9:38AM CDT
inVentiv Health Clinical, a leading global supplier of drug development services, announced today that it has been selected for an osteoarthritis Investigational New Drug Application (IND) by the innovative regenerative medicine biotechnology company IntelliCell BioSciences, Inc., (OTCQB:SVFC). IntelliCell will be studying the use of adult autologous vascular cells from blood vessels in adipose tissue to treat osteoarthritis of the knee.

IntelliCell BioSciences Has Engaged inVentiv Clinical as CRO for Osteoarthritis IND Lead by Dr. James Andrews
Marketwire - Mon Apr 14, 8:19AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stomovascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has engaged inVentiv Health Clinical as the Clinical Research Organization (CRO) for the conduct of a clinical trial in osteoarthritis of the knee under an Investigational New Drug Application (IND). Dr. James Andrews, the legendary orthopedic surgeon will be the principal investigator for the study.

IntelliCell BioSciences Announces That Dr. Steven Victor Was Thanked for His Work in Brain Trauma Research for Veterans
Marketwire - Thu Mar 27, 8:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that at the Stand For The Troops event in Washington, D.C. last Saturday, March 23, Major General John Batiste, US Army (Ret.) and Major Ben Richards, US Army (Ret.) the brain trauma veteran who received his purple heart, thanked our CEO, Steven Victor, MD for his help with brain trauma veterans.

IntelliCell BioSciences Announces That It Will Develop Investigational Clinical Protocol Studies for the Treatment of ALS With Dr. Manuel Trujillo
Marketwire - Mon Mar 24, 12:17PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it will be entering into a research collaboration with Dr. Manuel Trujillo, Clinical Psychiatry NYU Department of Psychiatry and Medical Director of the Amen Clinic, to use its unique approach to the harvest and use of autologous adipose derived stromal vascular fraction cells (SVFC) for clinical studies of ALS (Lou Gehrig's Disease).

IntelliCell BioSciences Announces It Will File an IND for Osteoarthritis of the Knee in Conjunction With the Andrews's Research and Educational Foundation
Marketwire - Mon Mar 17, 8:25AM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed consulting agreements with Dr Adam Anz and Dr Josh Hackel of the Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida. Intellicell will be filing an IND for the treatment of osteoarthritis of knee lead by Dr. James Andrews and conducted by Drs. Anz and Hackel for its Stromal Vascular Fraction Cells (SVFC).

IntelliCell BioSciences Joins Forces With Dr. James Andrews's Research and Educational Foundation
Marketwire - Wed Mar 12, 1:36PM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed a license agreement with Dr. James Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida for the installation of its cGTP Cellular Processing Lab for the manufacturing of Stromal Vascular Fraction Cells (SVFC).

IntelliCell BioSciences Raises Capital for Strategic Growth
Marketwire - Wed Mar 12, 12:59PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that it has closed on a round of financing from Yorkville Advisors, LLC.

Global Vending Machine Market 2014-2018
PR Newswire - Wed Jan 22, 9:29AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:

IntelliCell Biosciences Announces it Has Received Notification That International Patents for Canada, Europe and Korea Are Filed and Pending Approvals
ACCESSWIRE - Thu Sep 19, 1:05PM CDT
NEW YORK, NY, September 19, 2013 - (ACCESSWIRE)- IntelliCell Biosciences, Inc. ("Company" (OTC Pink: SVFC) announced today that it has received notification that the Canadian Application, No. 2823123, Entitled: ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USED THEREOF has been filed.

OTC Signal Daily Stock Watch - IntelliCell BioSciences (OTC:SVFC)
WorldStockWire - Sun Sep 08, 8:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com

IntelliCell BioSciences Discusses their Stem Cell Treatment Technology in Online Interview
ACCESSWIRE - Fri Jul 12, 11:32AM CDT
NEW YORK, NY, July 12, 2013 - (eTeligis via ACCESSWIRE) IntelliCell BioSciences, Inc. (OTC PINK: SVFC), a developer of novel, patented stromal vascular fraction cells (stem cells) technologies that address the regenerative, curative and preventative conditions of disease states, announces an online interview where they discuss their current SVF (stem cell) treatment technology.

Maxim Group Issues Stem Cell Sector Report on IntelliCell BioSciences Based on Treatment Process
ACCESSWIRE - Mon Jul 08, 12:01PM CDT
NEW YORK, July 08, 2013 (eTeligis via ACCESSWIRE) -- IntelliCell BioSciences, Inc. (OTCPINK: SVFC), a developer of novel, patented technology used to isolate stromal vascular fraction cells (stem cells) from adipose (fat) tissue. These cells are used to address the regenerative, curative and preventative conditions of disease, announced New York based Maxim Group has issued a research opinion on stem cell sector, and our position within the industry.

IntelliCell BioSciences Announces That Dr Zain Khalpey Has Joined Its Advisory Board
ACCESSWIRE - Mon Jun 17, 10:41AM CDT
NEW YORK, NY June 17, 2013 / -- IntelliCell BioSciences, Inc. ("Company" (OTC PINK: SVFC) announced today that Dr Zain Khalpey, MD, PhD, MRCS (Eng) Director, Heart Transplant Program & Mechanical Circulatory Support, Division of Cardiothoracic Surgery?Associate Professor of Surgery, Physiological Sciences & Biomedical Engineering, University of Arizona College of Medicine has joined the Advisory Board.

IntelliCell BioSciences Announces That Its Cellular Tissue Laboratory was inspected by FDA
PR Newswire - Fri Jun 14, 11:40AM CDT
IntelliCell BioSciences, Inc. ("Company" (OTC Pink: SVFC) announced today that on May 14, 2013 through June 2, 2013, its cellular laboratory facility underwent a thorough inspection by the FDA. The observations from the FDA inspection were provided to the company in the Form 483. The Company will respond to those observations in a timely manner. IntelliCell will take the necessary actions to address the relevant FDA observations.

IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
PR Newswire - Thu Jun 13, 11:53AM CDT
IntelliCell BioSciences, Inc. ("Company" (SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation has been made official. This technology involves an innovative mechanical method for the separation of stromal vascular fraction cells from adipose (fat) tissue, without the use of enzymes. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures. Investors can access the published patent at the US Patent website by entering the patent # 8,440,440. Link to patent website: http://patft.uspto.gov/netahtml/PTO/srchnum.htm

Symbotic Inc. (SYM) Stock Research Links

SYM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 101

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 96

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 183

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 49

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 25

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 217

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

BrainsWay Achieves Record Revenue and Strategic Growth in 2025

Updated Category News Views 256

Exploring BrainsWay's Remarkable Q2 Results BrainsWay Ltd. (NASDAQ: BWAY), a prominent player in neurostimulation treatments for mental health disorders, recently announced its extraordinary financial performance for the second quarter of 2025. The company achieved a record quarterly revenue of $12.6 million, marking a notable 26% increase compared to the same quarter in...

Continue Reading
CDC Foundation Pushes for Urgent Ebola Response

Updated Category News Views 33

Sounding the Alarm on Ebola In a world where crises come and go like the seasons, the latest Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda ought to command our undivided attention. We've seen this movie before, yet here we are with an Ebola variant—Bundibugyo this time—that threatens to spiral out of control. The CDC Foundation has sounded...

Continue Reading
Apple Faces Class Action Over Alleged AI Misrepresentation

Updated Category News Views 279

Apple's Legal Challenges: Class Action Lawsuit Over AI Features Pomerantz LLP has announced the initiation of a class action lawsuit against Apple Inc. (NASDAQ: AAPL) and select executives, focusing on claims surrounding the company’s advertised artificial intelligence capabilities. This legal action stems from allegations of misleading information disseminated to...

Continue Reading
Celebrate Togetherness with Aperol's Inaugural Aperolidays

Updated Category News Views 240

Introducing Aperolidays: A Celebration of Togetherness Aperol, the beloved Italian aperitivo, is stepping into the holiday spirit by announcing the inaugural Aperolidays. This unique celebration aims to infuse joy and connection into the winter season, inviting everyone to gather and enjoy the quintessential Italian way of life. New Festive Merchandise and Experiences...

Continue Reading
Acorai Unveils Breakthroughs in Heart Failure Monitoring Solutions

Updated Category News Views 233

Acorai's Impactful Results in Heart Failure Management Acorai, a clinical-stage company focused on innovative ways to manage heart failure, recently shared impressive findings from the extensive 1,600-patient CAPTURE-HF study. The study focused on a novel, non-invasive multi-sensor device aimed at improving the way healthcare professionals monitor heart failure patients....

Continue Reading